163 related articles for article (PubMed ID: 26496026)
1. VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
Schafroth C; Galván JA; Centeno I; Koelzer VH; Dawson HE; Sokol L; Rieger G; Berger MD; Hädrich M; Rosenberg R; Nitsche U; Schnüriger B; Langer R; Inderbitzin D; Lugli A; Zlobec I
Oncotarget; 2015 Dec; 6(39):41453-63. PubMed ID: 26496026
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.
Bledsoe JR; Kamionek M; Mino-Kenudson M
Am J Surg Pathol; 2014 Oct; 38(10):1418-28. PubMed ID: 24921639
[TBL] [Abstract][Full Text] [Related]
3. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
4. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
[TBL] [Abstract][Full Text] [Related]
5. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.
Mesteri I; Bayer G; Meyer J; Capper D; Schoppmann SF; von Deimling A; Birner P
Mod Pathol; 2014 Jan; 27(1):135-44. PubMed ID: 23887306
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
Kuan SF; Navina S; Cressman KL; Pai RK
Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
[TBL] [Abstract][Full Text] [Related]
9. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
[TBL] [Abstract][Full Text] [Related]
10. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
12. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test.
Hang JF; Li AF; Chang SC; Liang WY
Histopathology; 2016 Jul; 69(1):54-62. PubMed ID: 26588428
[TBL] [Abstract][Full Text] [Related]
15. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
17. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P
Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
[TBL] [Abstract][Full Text] [Related]
19. BRAF
Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
